SOURCE: American Association for Cancer Research

PHILADELPHIA — October 3, 2011 — Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinomas which derive from human papillomavirus (HPV) type 16, according to a study published in Clinical Cancer Research.

“This has immediate clinical applications as we consider recruitment to clinical trials designed to de-escalate the intensity of therapy based on HPV status” said lead researcher Andrew Schache, MD, University of Liverpool, Liverpool, United Kingdom.

Dr. Schache said that the attention surrounding HPV, particularly in the last several years, has given rise to a number of diagnostic tests, but the evaluation of these tests has lagged behind.

For the current study, researchers evaluated 8 possible combinations of known diagnostic tests on 108 cases of HPV16 derived oropharyngeal squamous cell carcinoma. They used viral gene expression as the standard marker.

“Viral gene expression has 100% specificity and sensitivity, but it requires very high quality tissue that is often not available,” said Dr. Schache.

After evaluating the tests, they found that a combination of DNA qPCR and P16 immunohistochemistry had 97% sensitivity and 94% specificity.

Both of these assays are commercially available in proprietary and generic forms, so the combination test could be administered.

“Getting the diagnosis right is extremely important because cases like this may receive less aggressive therapy based on a positive test,” added Dr. Schache. “You do not want to withhold treatment from a more aggressive case.”

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.